Novel Anti-Tau Seeding Antibody MK-2214 Achieves Near-Complete CSF Target Engagement in Phase 1

Phase 1 clinical pharmacology data for MK-2214, Merck's investigational monoclonal antibody targeting phosphorylated serine 413 (pS413) tau, demonstrated favorable tolerability and robust target engagement across three first-in-human studies, according to an abstract presented at the 2026 Alzheimer's Association International Conference (AAIC) in London.¹ A phase 2 efficacy trial, dubbed PARADIGM (NCT07033494) is now actively enrolling.

The key pharmacodynamic finding came from Study 3, the first to include cognitively impaired patients: free pS413 tau in the CSF was reduced below the limit of quantitation at IV doses of 20 mg and above at both day 29 and day 85.¹ The investigators characterized this as a high level of target engagement, essentially complete suppression of the free, extracellular pS413 tau pool at doses well below the maximum studied.

Across all three studies, MK-2214 was generally well-tolerated with no dose-limiting tolerability issues and no drug-related adverse event pattern. The half-life was approximately 80 days, consistent with the extended half-life engineering and supporting a monthly or less frequent dosing interval. Exposures and Cmax were approximately dose-proportional in each study. Subcutaneous bioavailability relative to IV was 0.63 across the 50 mg and 200 mg SC doses tested in Study 1.

Pharmacokinetics in Japanese participants in Study 2 and in cognitively impaired older adults in Study 3 were both comparable to those in healthy younger adults in Study 1, supporting consistent drug behavior across populations.

Led by Seth Robey, director of quantitative pharmacology and pharmacometrics at Merck Pharmaceuticals, the clinical pharmacology program comprised three randomized, double-blind, placebo-controlled studies. Study 1 was a first-in-human single ascending dose study in 64 healthy participants receiving MK-2214 IV at 10 to 4200 mg, or subcutaneously at 50 mg or 200 mg. Study 2 was a single ascending dose study (700 to 4200 mg IV) in 48 healthy Japanese men. Study 3 was a multiple ascending dose study in 34 participants aged 50 to 80 with mild-to-moderate cognitive impairment, receiving MK-2214 IV at 4 to 500 mg monthly for three doses.

READ MORE: Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3

The pS413 epitope is a post-translational modification present in pathological forms of tau and implicated in tau seeding and intercellular spread, the processes thought to drive the stereotyped progression of tau pathology across connected brain regions in Alzheimer's disease. Preclinical in vitro and in vivo seeding studies showed that antibodies targeting pS413 produced robust reductions in tau pathology, and blocking extracellular pS413 tau is hypothesized to reduce the prion-like propagation of tau seeds. MK-2214 was engineered with an extended half-life compared with traditional antibodies to support infrequent dosing.

The tau-targeting landscape in AD has had limited clinical success to date, with multiple anti-tau antibodies failing in phase 2 or 3 trials. The mechanistic focus on pS413 tau specifically, rather than total tau or paired helical filament tau, represents a more selective approach targeting the extracellular seeding-competent fraction believed to drive spread rather than intracellular accumulation.

As mentioned, the phase 2 PARADIGM study is now actively recruiting. Led by Lawren VandeVrede, MD, PhD, at the UCSF Memory and Aging Center, the study is a randomized, placebo-controlled, double-blind trial evaluating MK-2214 in participants with MCI or mild dementia due to early AD, with IV infusions every 4 weeks over up to 23 to 26 months.² Key endpoints include tau spread on PET imaging, CSF biomarkers, cognitive function, and activities of daily living.³

Click here for more AAIC 2026 coverage.

REFERENCES
1. Robey S, Kurz J, Cerchio K, et al. Phase 1 studies of MK-2214, a novel antibody targeting pS413 tau, for the treatment of Alzheimer's disease. Abstract presented at: Alzheimer's Association International Conference (AAIC); 2026; London, United Kingdom.
2. A clinical study of MK-2214 in people with early Alzheimer's disease. UCSF Memory and Aging Center. Accessed July 13, 2026. https://memory.ucsf.edu/research-trials/clinical-trials/mk-2214
3. Phase 2 randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of MK-2214 in participants with early Alzheimer's disease. ClinicalTrials.gov. NCT07033494. Accessed July 13, 2026. https://clinicaltrials.gov/study/NCT07033494